These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib. Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230 [No Abstract] [Full Text] [Related]
3. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. Kaneda H; Okamoto I; Nakagawa K J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271 [No Abstract] [Full Text] [Related]
4. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538 [TBL] [Abstract][Full Text] [Related]
5. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry. Feng Y; Singh AD; Lanigan C; Tubbs RR; Ma PC J Thorac Oncol; 2013 Dec; 8(12):e109-11. PubMed ID: 24389446 [No Abstract] [Full Text] [Related]
6. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. Toyokawa G; Hirai F; Inamasu E; Yoshida T; Nosaki K; Takenaka T; Yamaguchi M; Seto T; Takenoyama M; Ichinose Y J Thorac Oncol; 2014 Dec; 9(12):e86-7. PubMed ID: 25393798 [No Abstract] [Full Text] [Related]
7. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436 [TBL] [Abstract][Full Text] [Related]
8. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. Sun JM; Choi YL; Won JK; Hirsch FR; Ahn JS; Ahn MJ; Park K J Thorac Oncol; 2012 Dec; 7(12):e36-e38. PubMed ID: 23154564 [No Abstract] [Full Text] [Related]
9. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222 [TBL] [Abstract][Full Text] [Related]
10. Treatment and detection of ALK-rearranged NSCLC. Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207 [TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. Costa DB; Kobayashi S J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013 [No Abstract] [Full Text] [Related]
12. Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status. Li DL; Chen XR; Ma SX; Chen LK Thorac Cancer; 2016 Sep; 7(5):619-622. PubMed ID: 27766783 [TBL] [Abstract][Full Text] [Related]
13. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer? Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857 [TBL] [Abstract][Full Text] [Related]
14. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. Takeda M; Okamoto I; Nakagawa K J Thorac Oncol; 2013 May; 8(5):654-7. PubMed ID: 23584297 [TBL] [Abstract][Full Text] [Related]
15. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824 [No Abstract] [Full Text] [Related]
16. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569 [TBL] [Abstract][Full Text] [Related]
17. Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): a feasibility study. Zwaenepoel K; Merkle D; Cabillic F; Berg E; Belaud-Rotureau MA; Grazioli V; Herelle O; Hummel M; Le Calve M; Lenze D; Mende S; Pauwels P; Quilichini B; Repetti E Exp Mol Pathol; 2015 Feb; 98(1):113-8. PubMed ID: 25576649 [TBL] [Abstract][Full Text] [Related]